ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.975
-0.075 (-2.46%)
Apr 3, 2025, 2:55 PM EDT - Market open
ImmunityBio Employees
ImmunityBio had 680 employees as of December 31, 2024. The number of employees increased by 52 or 8.28% compared to the previous year.
Employees
680
Change (1Y)
52
Growth (1Y)
8.28%
Revenue / Employee
$21,684
Profits / Employee
-$608,182
Market Cap
2.54B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 680 | 52 | 8.28% |
| Dec 31, 2023 | 628 | -97 | -13.38% |
| Dec 31, 2022 | 725 | 138 | 23.51% |
| Dec 31, 2021 | 587 | 322 | 121.51% |
| Dec 31, 2019 | 265 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IBRX News
- 8 days ago - ImmunityBio to Host Investor Day - Business Wire
- 21 days ago - ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching - Business Wire
- 27 days ago - ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum - Seeking Alpha
- 4 weeks ago - ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024 - Business Wire
- 4 weeks ago - ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer - Business Wire
- 6 weeks ago - FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage - Business Wire
- 6 weeks ago - ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
- 2 months ago - ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer - Business Wire